En vivo
FierceBiotechClinical-stage cancer biotech Treeline sees path to public markets via reverse mergerFierceBiotechADA: Dexcom CGM shows benefit in non-insulin diabetes patientsEndpoints NewsTreeline to go public via reverse merger with Standard BioToolsFierceBiotechResmed snaps up Noctrix Health in $340M sleep tech dealBioWorldBiggest gainers and losers for June 1-5, 2026Endpoints NewsJ&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldFierceBiotechJ&J makes $1B upfront bet on emerging DAC space by netting Firefly BioEndpoints NewsGSK inks multi-target pact with Engitix; Sangamo considers strategic optionsEndpoints NewsTango plans Phase 3 pancreatic cancer study after combo successEndpoints NewsComing SoonEndpoints NewsBiopharma's top-paid CEOs of 2025: 25 making $25M+Endpoints NewsCavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
Endpoints News 18 dic 2025

Endpoints biopharma sentiment survey for Q1 2026

Endpoints biopharma sentiment survey for Q1 2026

Original
Contenido no disponible. Consulta la fuente original.